Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Exanthema × Hydrocortisone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Leukemia 13 Burkitt Lymphoma 11 Prostatic Neoplasms 9 Lymphoma 6 Leukemia, Biphenotypic, Acute 6 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Non-Hodgkin 3 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Follicular 2 Hodgkin Disease 2 Down Syndrome 2 Dendritic Cell Sarcoma, Interdigitating 2 Stomatitis 1 Rhabdoid Tumor 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Oral Ulcer 1 Neoplasms, Plasma Cell 1 Lymphoma, T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Mast-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Fulvestrant 2 ruxolitinib 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Prednisone 1 Panitumumab 1 Minocycline 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Gels 1 Erlotinib Hydrochloride 1 Doxycycline 1 Dapsone 1 Clindamycin 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡